为了系统地确定和叙述脂质体载体基因治疗对卵巢癌结局的证据。从开始到2023年7月7日，通过对Embase、MEDLINE和Web of Science的电子数据库进行检索，以确定调查脂质体载体基因治疗对卵巢癌结局影响的原始研究为目标。通过对纳入标准进行评估，检索获得了564份研究，其中75篇符合纳入标准。鉴定出4种主要类型的脂质体：阳离子、中性、聚合物包被和配体靶向脂质体。具有最多证据的脂质体是阳离子脂质体，其特点是其带正电的磷脂（n=37，49.3%）。同样，具有中性磷脂（如1,2-二油基-sn-甘油-3-磷脂酰胆碱）的脂质体也受到了高度的研究（n=25，33.3%）。确定了8个基因治疗研究领域，评估目标蛋白/转录本或分子途径：microRNAs、骚动蛋白A2型（EphA2）、白细胞介素、丝裂原活化蛋白激酶（MAPK）、人类端粒酶逆转录酶/E1A（hTERT/EA1）、自杀基因、p53和多药耐药突变体1（MDR1）。脂质体载体基因治疗对卵巢癌在许多体内研究中显示出很好的前景。新兴的聚合物包被和配体靶向脂质体因其更高的稳定性和特异性而受到关注。我们发现，microRNAs是最常研究的基因治疗方法。总体而言，脂质体基因治疗已被证明能减小肿瘤的大小和重量，并改善生存率。进一步研究卵巢癌基因治疗的载体和靶点可能是改善患者结局的有希望的途径。 © 2023. BioMed Central Ltd., part of Springer Nature.

To systematically identify and narratively synthesize the evidence surrounding liposomal delivery of gene therapy and the outcome for ovarian cancer.An electronic database search of the Embase, MEDLINE and Web of Science from inception until July 7, 2023, was conducted to identify primary studies that investigated the effect of liposomal delivery of gene therapy on ovarian cancer outcomes. Retrieved studies were assessed against the eligibility criteria for inclusion.The search yielded 564 studies, of which 75 met the inclusion criteria. Four major types of liposomes were identified: cationic, neutral, polymer-coated, and ligand-targeted liposomes. The liposome with the most evidence involved cationic liposomes which are characterized by their positively charged phospholipids (n = 37, 49.3%). Similarly, those with neutrally charged phospholipids, such as 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine, were highly researched as well (n = 25, 33.3%). Eight areas of gene therapy research were identified, evaluating either target proteins/transcripts or molecular pathways: microRNAs, ephrin type-A receptor 2 (EphA2), interleukins, mitogen-activated protein kinase (MAPK), human-telomerase reverse transcriptase/E1A (hTERT/EA1), suicide gene, p53, and multidrug resistance mutation 1 (MDR1).Liposomal delivery of gene therapy for ovarian cancer shows promise in many in vivo studies. Emerging polymer-coated and ligand-targeted liposomes have been gaining interest as they have been shown to have more stability and specificity. We found that gene therapy involving microRNAs was the most frequently studied. Overall, liposomal genetic therapy has been shown to reduce tumor size and weight and improve survivability. More research involving the delivery and targets of gene therapy for ovarian cancer may be a promising avenue to improve patient outcomes.© 2023. BioMed Central Ltd., part of Springer Nature.